Records containing: Resectable Hepatocellular Carcinoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-24Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Hepatocellular Carcinoma (ATHENA)
-
CLINICAL_TRIALS study record update · 2026-04-01A Phase II Prospective Study to Evaluate the Safety and Efficacy of Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.
-
CLINICAL_TRIALS study record update · 2026-03-09PET Imaging of Hepatocellular Carcinoma With 18F-FSPG
-
CLINICAL_TRIALS study record update · 2026-03-05An Open-Label, Phase II, Pre-Operative Study of Atezolizumab Plus Bevacizumab for Resectable Hepatocellular Carcinoma
-
CLINICAL_TRIALS study record update · 2026-03-03A Phase Ib Open-label, Randomized Trial Evaluating Neoadjuvant Ateganosine and Cadonilimab in Resectable Hepatocellular Carcinoma
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-10-01A Pilot Study of Neoadjuvant Stereotactic Beam Radiation Therapy Followed by Atezolizumab and Bevacizumab in Resectable Hepatocellular Carcinoma
-
CLINICAL_TRIALS study record update · 2025-09-02A Phase 1 Neoadjuvant Trial of Selective Internal Yttrium-90 Radioembolization (SIRT) With Tremelimumab and Durvalumab (MEDI4736) for Resectable Hepatocellular Carcinoma
-
CLINICAL_TRIALS study record update · 2025-06-13A Phase II, Randomized, Open-label, National, Multicenter Study Evaluating the Efficacy and Safety of the Combination of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in Hepatocellular Carcinoma (ASPIRE)
-
CLINICAL_TRIALS study record update · 2024-12-03A Prospective, One-arm, Phase II Clinical Study of Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma With a High Risk of Recurrence
-
CLINICAL_TRIALS study record update · 2024-10-15Neoadjuvant Transcatheter Arterial Chemoembolization Combined With Lenvatinib Plus Cadonilimab for Resectable Hepatocellular Carcinoma: A Single-Arm Phase II Clinical Trial
-
CLINICAL_TRIALS study record update · 2024-07-29Neoadjuvant Stereotactic Body Radiotherapy (SBRT) Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma With Macrovascular Invasion: A Single-arm, Phase II Study
-
CLINICAL_TRIALS study record update · 2023-08-28Surgical Resection for Hepatocellular Carcinoma: a Single-Center's One Decade of Experience
-
CLINICAL_TRIALS study record update · 2023-07-10An Open-Label Preoperative Pilot Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable (HCC)
-
CLINICAL_TRIALS study record update · 2023-02-16A Pre-Operative Study Evaluating Nivolumab Plus ADI-PEG 20 in Patients With Resectable Hepatocellular Carcinoma
-
CLINICAL_TRIALS study record update · 2022-12-15Neoadjuvant Immune-Checkpoint Blockade Therapy Combining With TACE For Resectable Hepatocellular Carcinoma With High Recurrence Risk: A Phase II, Single-arm Clinical Trial
-
CLINICAL_TRIALS study record update · 2022-08-29A Prospective, Two-arm, Randomized，Phase II Clinical Study of Sintilimab Combined With Lenvatinib Versus Hepatic Artery Infusion Chemotherapy for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma With a High Risk of Recurrence.
-
CLINICAL_TRIALS study record update · 2021-04-08A Prospective, One-arm, Phase II Clinical Study of Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma With a High Risk of Recurrence.
-
CLINICAL_TRIALS study record update · 2016-10-04A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors